A NEW medication for patients with severe eczema (atopic dermatitis) is now available in Australia.

Patients aged 12 years and above can now access a new medication DUPIXENT (Dupilumab) to treat severe eczema. DUPIXENT is available on the Pharmaceutical Benefits Scheme (PBS) from March 2021 for patients with moderate to severe eczema who have failed to respond to other treatments of eczema.  

PBS listing of Dupixent (dupilumab) for severe atopic dermatitis – Australasian Society of Clinical Immunology and Allergy (ASCIA)